This year, the liquidity market has exhibited some unique patterns. Total IPOs are up year-to-year, but the M&A market is falling. As discussed earlier this summer, biotech IPOs are seeing a huge resurgence. That sector (along with technology) is getting equally as much attention in the securities litigation arena, as reported in our most recent D&O Databox. Navigating liquidity options has become that much more challenging. But a successful IPO or merger is very possible.
The Fall 2013 San Francisco Liquidity Summit on September 20th to is designed for companies considering a liquidity event in the near or longer term, in the form of a public offering or merger. I will be moderating the “nuts & bolts” panel. The panel will include Scott Darling, Vice President and General Counsel, Trulia; John Kelm, Audit Partner, Deloitte and Touche LLP; Sri Kosaraju, Managing Director, Equity Capital Markets, J.P. Morgan; and Gabriella Lombardi, Partner, Pillsbury.
Click here for registration and seminar details. Hope you will be able to join us.
The views expressed in this blog are solely those of the author. This blog should not be taken as insurance or legal advice for your particular situation. Questions? Comments? Concerns? Email: firstname.lastname@example.org.